Analgesic effect of a mixed T-type channel inhibitor/CB2 receptor agonist

Molecular Pain

Volumn 9, Issue 1, 2013, Pages

  Gadotti, Vinicius M ^a   You, Haitao ^a   Petrov, Ravil R ^b   Berger, N Daniel ^a   Diaz, Philippe ^b   Zamponi, Gerald W ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

Cannabinoid Receptors; Mice; Pain; Patch Clamp; T type Channels

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANALGESIC AGENT; CALCIUM CHANNEL T TYPE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); NMP 181; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERALGESIA; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOASSAY;

ANALGESICS; ANIMALS; CALCIUM CHANNELS, T-TYPE; CARBAZOLES; CHO CELLS; CRICETULUS; HEK293 CELLS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MORPHOLINES; PAIN MEASUREMENT; PYRAZOLES; RECEPTOR, CANNABINOID, CB2;

EID: 84879492263     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-9-32     Document Type: Article

References (60)

1. Horvath G, Kekesi G, Tuboly G, Benedek G. Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level. Brain Res 2007, 1155:42-48.
2. Chemin J, Monteil A, Perez-Reyes E, Bourinet E, Nargeot J, Lory P. Specific contribution of human T-type calcium channel isotypes (alpha(1G), alpha(1H) and alpha(1I)) to neuronal excitability. J Physiol 2002, 540:3-14. 10.1113/jphysiol.2001.013269, 2290209, 11927664.
3. Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003, 83:117-161.
4. Shin HS, Cheong EJ, Choi S, Lee J, Na HS. T-type Ca2+ channels as therapeutic targets in the nervous system. Curr Opin Pharmacol 2008, 8:33-41. 10.1016/j.coph.2007.12.003, 18203662.
5. Cain SM, Snutch TP. Contributions of T-type calcium channel isoforms to neuronal firing. Channels (Austin) 2010, 4:475-482.
6. Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 2009, 60:84-89. 10.1016/j.brainresrev.2008.12.021, 2692704, 19162069.
7. Marger F, Gelot A, Alloui A, Matricon J, Ferrer JF, Barrère C, Pizzoccaro A, Muller E, Nargeot J, Snutch TP, et al. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc Natl Acad Sci USA 2011, 108:11268-11273. 10.1073/pnas.1100869108, 3131334, 21690417.
8. Todorovic SM, Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br J Pharmacol 2011, 163:484-495. 10.1111/j.1476-5381.2011.01256.x, 3101611, 21306582.
9. Bourinet E, Zamponi GW. Voltage gated calcium channels as targets for analgesics. Curr Top Med Chem 2005, 5:539-546. 10.2174/1568026054367610, 16022676.
10. Matthews EA, Dickenson AH. Effects of ethosuximide, a T-type Ca2+ channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol 2001, 415:141-149. 10.1016/S0014-2999(01)00812-3, 11274992.
11. Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, Uebele VN, Renger JJ, Eschalier A, Ardid D, et al. State-dependent properties of a new T-type calcium channel blocker enhance CaV3.2 selectivity and support analgesic effects. Pain 2013, 154:283-293. 10.1016/j.pain.2012.10.023, 23257507.
12. Bourinet E, Alloui A, Monteil A, Barrère C, Couette B, Poirot O, Pages A, McRory J, Snutch TP, Eschalier A, Nargeot J, et al. Silencing of the CaV3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005, 24:315-324. 10.1038/sj.emboj.7600515, 545807, 15616581.
13. Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, Orestes P, Latham JR, Todorovic SM, Jevtovic-Todorovic V. In vivo silencing of the CaV3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. Pain 2009, 145:184-195. 10.1016/j.pain.2009.06.012, 2735619, 19577366.
14. Matsunami M, Miki T, Nishiura K, Hayashi Y, Okawa Y, Nishikawa H, Sekiguchi F, Kubo L, Ozaki T, Tsujiuchi T, et al. Kawabata A. Involvement of the endogenous hydrogen sulfide/CaV3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice. Br J Pharmacol 2012, 167:917-928. 10.1111/j.1476-5381.2012.02060.x, 22646666.
15. Jacus MO, Uebele VN, Renger JJ, Todorovic SM. Presynaptic CaV3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J Neurosci 2012, 32:9374-9382. 10.1523/JNEUROSCI.0068-12.2012, 3398424, 22764245.
16. Todorovic SM, Jevtovic-Todorovic V. Neuropathic pain: role for presynaptic T-type channels in nociceptive signaling. Pflugers Arch in press.
17. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006, 147(Suppl 1):163-171.
18. Gertsch J, Pertwee RG, Di Marzo V. Phytocannabinoids beyond the Cannabis plant - do they exist?. Br J Pharmacol 2010, 160:523-529. 10.1111/j.1476-5381.2010.00745.x, 2931553, 20590562.
19. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and funcional expression of the cloned cDNA. Nature 1990, 346:561-564. 10.1038/346561a0, 2165569.
20. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65. 10.1038/365061a0, 7689702.
21. Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain 2013, 29:162-171. 10.1097/AJP.0b013e31824c5e4c, 22367503.
22. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs 2011, 25:187-201. 10.2165/11539000-000000000-00000, 21323391.
23. Pryce G, Baker D. Potential control of multiple sclerosis by cannabis and the endocannabinoid system. CNS Neurol Disord Drug Targets 2012, 11:624-641. 10.2174/187152712801661310, 22583441.
24. Trotter BW, Nanda KK, Burgey CS, Potteiger CM, Deng JZ, Green AI, Hartnett JC, Kett NR, Wu Z, Henze DA, et al. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy. Bioorg Med Chem Lett 2011, 21:2354-2358. 10.1016/j.bmcl.2011.02.082, 21420860.
25. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 1999, 288:478-483.
26. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. Embo J 2001, 20:7033-7040. 10.1093/emboj/20.24.7033, 125779, 11742980.
27. Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E, Chemin J. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci 2009, 29:13106-13114. 10.1523/JNEUROSCI.2919-09.2009, 19846698.
28. Ross HR, Gilmore AJ, Connor M. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol 2009, 156:740-750. 10.1111/j.1476-5381.2008.00072.x, 2697747, 19226289.
29. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006, 66:234-246. 10.1016/j.mehy.2005.08.026, 16209908.
30. Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 2008, 283:16124-16134. 10.1074/jbc.M707104200, 3259625, 18390906.
31. You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P. Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. Mol Pain 2011, 7:89. 10.1186/1744-8069-7-89, 3250956, 22093952.
32. Bladen C, Zamponi GW. Common mechanisms of drug interactions with sodium and T-type calcium channels. Mol Pharmacol 2012, 82:481-487. 10.1124/mol.112.079715, 22695716.
33. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987, 30:103-114. 10.1016/0304-3959(87)90088-1, 3614974.
34. Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, Park J, Chen CC, Campbell KP, Shin HS. Attenuated pain responses in mice lacking CaV3.2 T-type channels. Genes Brain Behav 2007, 6:425-431. 10.1111/j.1601-183X.2006.00268.x, 16939637.
35. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784. 10.1038/nrd1495, 15340387.
36. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 2010, 11:51-62.
37. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2013, 4:873-884.
38. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005, 2:29-41. 10.1186/1742-2094-2-29, 1352348, 16343349.
39. Whiteside GT, Lee GP, Valenzano KJ. The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 2007, 14:917-936. 10.2174/092986707780363023, 17430144.
40. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36. 10.1038/nrn2533, 2752436, 19096368.
41. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992, 89:3825-3829. 10.1073/pnas.89.9.3825, 525583, 1315042.
42. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma AL, Mitchell RL. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48:443-450.
43. Pan X, Ikeda SR, Lewis DL. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol Pharmacol 1996, 49:707-714.
44. Gilmore AJ, Heblinski M, Reynolds A, Kassiou M, Connor M. Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT. Br J Pharmacol 2012, 167:1076-1088. 10.1111/j.1476-5381.2012.02047.x, 22624680.
45. Tjølsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain 1992, 51:5-17. 10.1016/0304-3959(92)90003-T, 1454405.
46. Basbaum AI. Spinal mechanisms of acute and persistent pain. Reg Anesth Pain Med 1999, 24:59-67.
47. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986, 237:1001-1011.
48. Osawa Y, Oda A, Iida H, Tanahashi S, Dohi S. The effects of class Ic antiarrhythmics on tetrodotoxin-resistant Na+ currents in rat sensory neurons. Anesth Analg 2004, 99:464-471.
49. Ragsdale DS, Scheuer T, Catterall WA. Frequency and voltage-dependent inhibition of type IIA Na+ channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Mol Pharmacol 1991, 40:756-765.
50. Gérard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991, 279:129-134. 1151556, 1718258.
51. You H, Altier C, Zamponi GW. CCR2 receptor ligands inhibit CaV3.2 T-type calcium channels. Mol Pharmacol 2010, 77:211-217. 10.1124/mol.109.059022, 19864434.
52. Armbruster BN, Roth BL. Mining the receptorome. J Biol Chem 2005, 280:5129-5132.
53. Strachan RT, Ferrara G, Roth BL. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov Today 2006, 11:708-716. 10.1016/j.drudis.2006.06.012, 16846798.
54. Jensen NH, Roth BL. Massively parallel screening of the receptorome. Comb Chem High Throughput Screen 2008, 11:420-426. 10.2174/138620708784911483, 18673270.
55. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, Brown DL. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 2008, 155:1104-1116. 2597252, 18846037.
56. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67:313-316. 10.1016/0014-2999(80)90515-4, 6893963.
57. Gadotti VM, Zamponi GW. Cellular prion protein protects from inflammatory and neuropathic pain. Mol Pain 2011, 7:59. 10.1186/1744-8069-7-59, 3170224, 21843375.
58. Chen CC, Lamping KG, Nuno DW, Barresi R, Prouty SJ, Lavoie JL, Cribbs LL, England SK, Sigmund CD, Weiss RM. Abnormal coronary function in mice deficient in alpha1H T-type Ca2+ channels. Science 2003, 302:1416-1418. 10.1126/science.1089268, 14631046.
59. Paszcuk AF, Gadotti VM, Tibola D, Quintão NL, Rodrigues AL, Calixto JB, Santos AR. Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. Brain Res 2007, 1159:124-133.
60. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacology 2012, 62:419-426. 10.1016/j.neuropharm.2011.08.018, 21867719.